CoreWeave Just Changed The Game

CoreWeave's Q1 revenue surged over 420%, and the company projects FY2026 revenue between $6.0B and $7.48B with EBITDA margins normalizing at 30-32%, yielding $1.79B to $2.39B in EBITDA. Despite a $29.9 billion revenue backlog, the company's current valuation at 22-29x forward EV/EBITDA leaves limited multiple expansion, with a 25x multiple on FY2026 EBITDA implying a $59.8B valuation, offering only 15% upside from current levels.

Analysis

CoreWeave has demonstrated exceptional top-line momentum, evidenced by a Q1 revenue surge exceeding 420% and a substantial revenue backlog of $29.9 billion, of which 20-25% is anticipated to convert annually over the next four to five years. This backlog underpins FY2026 revenue projections ranging from $6.0 billion to $7.48 billion. Concurrently, EBITDA margins are forecast to normalize between 30-32%, translating to an estimated FY2026 EBITDA of $1.79 billion to $2.39 billion. Despite these strong fundamentals and significant events like a mentioned $4 billion OpenAI expansion, CoreWeave's current enterprise value of $52 billion places it at a demanding 22-29x forward EV/EBITDA multiple based on FY2026 estimates. An application of a 25x multiple to the projected FY2026 EBITDA suggests a target valuation of $59.8 billion, offering approximately 15% upside from current levels, indicating that while revenue visibility is high, further multiple expansion may be limited based on these specific projections. The reporting analyst, however, maintains a view that the firm’s long-term value remains underestimated, even after the stock’s significant appreciation and post-earnings bounce.

Key Decisions for Investors

• Investors should acknowledge CoreWeave's robust revenue growth and significant backlog, which provide strong visibility into future earnings, yet also note the current valuation already reflects much of this optimism at 22-29x FY2026 EV/EBITDA.
• Careful monitoring of backlog conversion rates and sustained EBITDA margin performance towards the targeted 30-32% will be crucial to validate the growth narrative and support the current valuation.
• Consideration should be given to the calculated 15% upside based on a 25x FY2026 EBITDA multiple, weighing this against the analyst's qualitative assertion of underestimated long-term value, particularly after the stock's substantial recent gains.